Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLYME: Saccharomyces boulardii during amoxicillin therapy for erythema migrans
2023-508694-80-01Phase 4Authorised
- Sponsor
- Biocodex
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, double-blind trial in antibiotic-associated diarrhea (AAD) comparing Enterol + amoxicillin with Placebo + amoxicillin (2 arms). Primary endpoint: Gut microbiota diversity changes. Planned start Jun 2024; status: authorised.
02
Drugs
piromidic acid
03
Conditions
antibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on 2023-508694-80-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508694-80-01.